ICIs, with their ability to block inhibitory pathways such as anti-programmed death-ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), have emerged as a cornerstone of cancer immunotherapy. This evidence concerns the gene CTLA4 and cancer.